<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2176-6223</journal-id>
<journal-title><![CDATA[Revista Pan-Amazônica de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pan-Amaz Saude]]></abbrev-journal-title>
<issn>2176-6223</issn>
<publisher>
<publisher-name><![CDATA[Instituto Evandro Chagas. Secretaria de Vigilância em Saúde e Ambiente. Ministério da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2176-62232016000400013</article-id>
<article-id pub-id-type="doi">10.5123/s2176-62232016000400013</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Análise de metanálises e ensaios clínicos relativos à utilização de estatinas em doenças cardiovasculares]]></article-title>
<article-title xml:lang="en"><![CDATA[Analysis of meta-analyses and clinical trials concerning the use of statins in cardiovascular diseases]]></article-title>
<article-title xml:lang="es"><![CDATA[Análisis de meta-análisis y ensayos clínicos relativos a la utilización de estatinas en enfermedades cardiovasculares]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Hudson Lacerda da]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[Naira Villas Boas de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[Orenzio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitário de Juiz de Fora  ]]></institution>
<addr-line><![CDATA[Juiz de Fora Minas Gerais]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Federal do Rio de Janeiro Faculdade de Farmácia Centro de Ciências da Saúde]]></institution>
<addr-line><![CDATA[Rio de Janeiro Rio de Janeiro]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade Federal do Pará Faculdade de Farmácia Instituto de Ciências da Saúde]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>7</volume>
<numero>4</numero>
<fpage>107</fpage>
<lpage>119</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S2176-62232016000400013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S2176-62232016000400013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S2176-62232016000400013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  OBJETIVO: Buscar evidências para a utilização das estatinas em doenças cardiovasculares e seus custos econômicos no contexto do Sistema Único de Saúde.  MÉTODOS: Trata-se de uma pesquisa exploratória, bibliográfica, de natureza qualitativa, realizada por meio de coleta de dados a partir da revisão sistemática.  RESULTADOS: Evidenciou-se que o tratamento com estatinas tem demonstrado ser custo-efetivo na prevenção de doenças cardiovasculares para pacientes com alto risco, quando da redução de desfechos a um baixo custo, especialmente em prevenção secundária.  CONCLUSÃO: Infere-se a necessidade de se rever as diretrizes clínicas quanto à aplicação do conceito de custo-efetividade e o financiamento das estatinas do componente básico e especializado (alto custo) para a utilização da sinvastatina e da atorvastatina e suas relações com a prevenção primária e secundária de doenças cardiovasculares.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  OBJECTIVE: To seek evidences for the use of statins in cardiovascular diseases and their economic costs in the context Unified Health System (Sistema Único de Saúde).  METHODS: This is an exploratory, a bibliographic and qualitative research performed by data collection method from the systematic review.  RESULTS: It was observed that the treatment with statins have been considered cost-effective in preventing cardiovascular diseases for high-risk users, when there is reduction of outcomes at low cost, especially in secondary prevention.  CONCLUSION: It is necessary to review the clinical guidelines about the application of the cost-effectiveness concept and the funding of basic and specialized component of statins (high cost) for the use of simvastatin and atorvastatin and their relationship with the primary and secondary prevention of cardiovascular diseases.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  OBJETIVO:  Buscar evidencias para la utilización de las estatinas en enfermedades cardiovasculares y sus costos económicos dentro del contexto del Sistema Único de Saúde. MÉTODOS: Se trata de una investigación exploratoria, bibliográfica, de naturaleza cualitativa realizada por medio de colecta de datos a partir de la revisión sistemática.  RESULTADOS:  Queda evidente que el tratamiento con estatinas ha demostrado ser costo-efectivo en la prevención de enfermedades cardiovasculares para pacientes con alto riesgo, por la reducción de desenlaces a bajo costo, especialmente en prevención secundaria.  CONCLUSIÓN:  Se concluye la necesidad de rever las directrices clínicas con relación a la aplicación del concepto de costo-efectividad y la financiación de las estatinas del componente básico y especializado (alto costo) para la utilización de la simvastatina y la atorvastatina y sus relaciones con la prevención primaria y secundaria de enfermedades cardiovasculares.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Inibidores de Hidroximetilglutaril-CoA Redutases]]></kwd>
<kwd lng="pt"><![CDATA[Doenças Cardiovasculares]]></kwd>
<kwd lng="pt"><![CDATA[Farmacoeconomia]]></kwd>
<kwd lng="en"><![CDATA[HMG-CoA Reductase Inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular Diseases]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de Hidroximetilglutaril-CoA Reductasas]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades Cardiovasculares]]></kwd>
<kwd lng="es"><![CDATA[Farmacoeconomía.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Endo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kuroda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tsujita]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum]]></article-title>
<source><![CDATA[J Antibiot]]></source>
<year>1976</year>
<volume>29</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1346-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alberts]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kuron]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Huff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1980</year>
<volume>77</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3957-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estatinas hipolipêmicas e novas tendências terapêuticas]]></article-title>
<source><![CDATA[Quim Nova]]></source>
<year>2007</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>425-30</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Cardiovascular diseases (CVDs)]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Izar]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Faria Neto]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Assad]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[VZ]]></given-names>
</name>
<name>
<surname><![CDATA[Sposito]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2013</year>
<volume>101</volume>
<numero>4^ssupl 1</numero>
<issue>4^ssupl 1</issue>
<supplement>supl 1</supplement>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grasiela]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wilton]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Andressa]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
<name>
<surname><![CDATA[Felipe]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Renata]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Danilo]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortalidade em idosos por doenças cardiovasculares: análise comparativa de dois quinquênios]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2015</year>
<volume>105</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>371-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos</collab>
<source><![CDATA[Relação nacional de medicamentos essenciais: Rename, 2010]]></source>
<year>2010</year>
<edition>7. ed</edition>
<page-range>250</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos</collab>
<source><![CDATA[Relação nacional de medicamentos essenciais: Rename, 2014]]></source>
<year>2015</year>
<edition>9. ed</edition>
<page-range>228</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde</collab>
<article-title xml:lang=""><![CDATA[Portaria nº 533, de 28 de março de 2012. Estabelece o elenco de medicamentos e insumos da Relação Nacional de Medicamentos Essenciais (RENAME) no âmbito do Sistema Único de Saúde (SUS)]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2012</year>
<page-range>96</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[DF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde</collab>
<article-title xml:lang=""><![CDATA[Portaria nº 1.015, 20 de dezembro de 2002. Protocolo Clínico e Diretrizes Terapêuticas - Dislipidemias]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2002</year>
<page-range>243-4</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[DF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde</collab>
<article-title xml:lang=""><![CDATA[Portaria nº 3.439, de 11 de novembro de 2010. Altera os artigos. 3º, 15, 16 e 63 e os Anexos I, II, III, IV e V à Portaria nº 2.981/GM/MS, de 26 de novembro de 2009, republicada em 1º de dezembro de 2009]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2010</year>
<page-range>31</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[DF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde</collab>
<article-title xml:lang=""><![CDATA[Portaria nº 200, de 25 de fevereiro de 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Dislipidemia para a prevenção de eventos cardiovasculares e pancreatite]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2013</year>
<page-range>116</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[DF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Atenção Básica</collab>
<source><![CDATA[Prevenção clínica de doença cardiovascular, cerebrovascular e renal crônica]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia</collab>
<source><![CDATA[Diretrizes metodológicas: estudos de avaliação econômica de tecnologias em saúde]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moraz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Garcez]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Assis]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Barcellos]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Kroeff]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudos de custo-efetividade em saúde no Brasil: uma revisão sistemática]]></article-title>
<source><![CDATA[Cienc Saude Coletiva]]></source>
<year>2015</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3211-29</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preço dos medicamentos utilizados nas doenças cardiovasculares no Brasil]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2012</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McCulloch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gorman]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Enanoria]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic reviews and meta-analyses: an illustrated, step-by-step guide]]></article-title>
<source><![CDATA[Natl Med J India]]></source>
<year>2004</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>86-95</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JPT]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane handbook for systematic reviews of interventions]]></source>
<year>2009</year>
<edition>Version 5.1.0</edition>
<publisher-loc><![CDATA[London (UK) ]]></publisher-loc>
<publisher-name><![CDATA[Cochrane Collaboration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>Universidade Federal de São Paulo</collab>
<source><![CDATA[Curso de revisão sistemática e metanálise]]></source>
<year>2012</year>
<publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
<publisher-name><![CDATA[UNIFESP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shepherd]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cobbe]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Isles]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Lorimer]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[MacFarlane]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of coronary heart disease with pravastatin in men with hypercolesterolemia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>333</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1301-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Kjekshus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pyörälä]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Olsson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Musliner]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1998</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LaRosa]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vupputuri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1999</year>
<volume>282</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2340-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Wilhelmsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Faergeman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Strandberg]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Thorgeirsson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Troedsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2000</year>
<volume>86</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>257-62</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ganz]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuntz]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Avorn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy in older patients with myocardialinfarction]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2000</year>
<volume>132</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>780-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<collab>Heart Protection Study Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebocontrolled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<numero>9326</numero>
<issue>9326</issue>
<page-range>7-22</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<collab>LIPID Study Group</collab>
<article-title xml:lang=""><![CDATA[Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<numero>9315</numero>
<issue>9315</issue>
<page-range>1379-87</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kulbertus]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Scheen]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PROSPER Study (Prospective study of pravastatin in the elderly at risk)]]></article-title>
<source><![CDATA[Rev Med Liege]]></source>
<year>2002</year>
<volume>57</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>809-13</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sever]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlöf]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Wedel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Beevers]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Caulfield]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>361</volume>
<numero>9364</numero>
<issue>9364</issue>
<page-range>1149-58</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vrecer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Turk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Drinovec]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mrhar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: meta-analysis of randomized trials]]></article-title>
<source><![CDATA[Int J Clin Pharmacol Ther]]></source>
<year>2003</year>
<volume>41</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>567-77</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hooper]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Summerbell]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Worthington]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Ness]]></surname>
<given-names><![CDATA[Andrew]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omega 3 fatty acids for prevention and treatment of cardiovascular disease]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2004</year>
<numero>4</numero>
<issue>4</issue>
<page-range>CD003177</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vijan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hayward]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2004</year>
<volume>140</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>650-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vaz Carneiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2006</year>
<volume>332</volume>
<numero>7550</numero>
<issue>7550</issue>
<page-range>1115-24</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Swanson]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tataronis]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin-related adverse events: a meta-analysis]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2006</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-35</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rachlis]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Devereaux]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Perri]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2008</year>
<volume>52</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1769-81</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afilalo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duque]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Steele]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jukema]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Craen]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenberg]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2008</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-45</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Josan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Majumdar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[McAlister]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2008</year>
<volume>178</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>576-84</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brugts]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yetgin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeks]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Gotto]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Shepherd]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Westendorp]]></surname>
<given-names><![CDATA[RGJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2009</year>
<volume>338</volume>
<numero>b2376</numero>
<issue>b2376</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pletcher]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lazar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bibbins-Domingo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodondi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Coxson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2009</year>
<volume>150</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>243-54</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<collab>Heart Protection Study Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Statin cost-effectiveness in the United States for people at different vascular risk levels]]></article-title>
<source><![CDATA[Circ Cardiovasc Qual Outcomes]]></source>
<year>2009</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-72</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Capewell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Critchley]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary mortality declines in the U.S. between 1980 and 2000: quantifying the contributions from primary and secondary prevention]]></article-title>
<source><![CDATA[Am J Prev Med]]></source>
<year>2010</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>228-34</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Seshasai]]></surname>
<given-names><![CDATA[SRK]]></given-names>
</name>
<name>
<surname><![CDATA[Erqou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sever]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jukema]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65.229 participants]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2010</year>
<volume>170</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1024-31</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caterina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Scarano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marfisi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lucisano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tatasciore]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>198-211</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegelmann]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Stella]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Costa Vieira]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Restelatto]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2013</year>
<volume>166</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>431-9</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araujo]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro de Souza]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Bahia]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Rey]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Santos Junior]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tura]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2011</year>
<volume>14</volume>
<numero>5^sSuppl 1</numero>
<issue>5^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S29-32</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Atenção Básica</collab>
<source><![CDATA[Política nacional de alimentação e nutrição]]></source>
<year>2003</year>
<edition>2. ed</edition>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Coordenação-Geral da Política de Alimentação e Nutrição</collab>
<source><![CDATA[Guia alimentar para a população brasileira: promovendo a alimentação saudável]]></source>
<year>2005</year>
<page-range>236</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="">
<collab>Agência Nacional de Vigilância Sanitária (BR)</collab>
<source><![CDATA[Estatinas na prevenção primária de eventos cardiovasculares. BRATS]]></source>
<year>2009</year>
<volume>4</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Abbot]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence e prognosis of unrecognized myocardial infarction: an update on de Framingham study]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1984</year>
<volume>311</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1144-7</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lotufo]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[O escore de risco de Framingham para doenças cardiovasculares]]></article-title>
<source><![CDATA[Rev Med]]></source>
<year>2008</year>
<volume>87</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>232-7</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wannmacher]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<source><![CDATA[Uso racional de estatinas na prevenção de cardiopatia isquêmica]]></source>
<year>2010</year>
<page-range>13</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawber]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Meadors]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[JRF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological approaches to heart disease: the Framingham study]]></article-title>
<source><![CDATA[Am J Public Health Nations Health]]></source>
<year>1951</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>279-86</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
